What one share of Citius Pharmaceuticals holds
Cranford, New Jersey, is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and unique prescription products.
Citius Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$2.13 |
|---|---|
| Cash and investments | $0.62 |
| Debt | $11.16 |
| Book value | $2.43 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2012 | — | −$22.50 | — | — | — | −$33.62 |
| 2013 | — | −$26.25 | — | — | — | −$61.28 |
| 2014 | — | −$15.00 | — | — | — | −$9.27 |
| 2015 | — | −$34.19 | — | — | — | −$6.98 |
| 2016 | — | −$57.24 | — | — | $225.00 | $85.97 |
| 2017 | $0.23 | −$47.36 | $0.01 | −$36.36 | — | $65.74 |
| 2018 | $0.17 | −$29.20 | — | — | — | $47.29 |
| 2019 | $0.11 | −$19.30 | — | — | — | $23.46 |
| 2020 | $0.06 | −$11.20 | $0.00 | −$10.81 | — | $15.15 |
| 2021 | $0.02 | −$5.64 | $0.00 | −$5.58 | — | $22.64 |
| 2022 | $0.02 | −$5.76 | — | — | — | $17.58 |
| 2023 | — | −$5.57 | — | — | — | $14.29 |
| 2024 | — | −$5.97 | — | — | — | $9.67 |
| 2025 | — | −$3.38 | — | — | — | $3.74 |
Common questions about Citius Pharmaceuticals
How much does one share of Citius Pharmaceuticals earn?
Over the last 12 months, Citius Pharmaceuticals lost $2.13 for each share.
Does Citius Pharmaceuticals pay a dividend?
Citius Pharmaceuticals didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Citius Pharmaceuticals’s book value per share?
Citius Pharmaceuticals’s book value is $2.43 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Citius Pharmaceuticals have?
Each share of Citius Pharmaceuticals has $0.62 of cash and investments and $11.16 of debt, as of June 30, 2026.
Has Citius Pharmaceuticals bought back shares?
Citius Pharmaceuticals’s share count rose about 24470% from 2012 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.